Printer Friendly

Corporate Profile for ThermoGenesis Corp., dated June 18, 1999.

--(BUSINESS WIRE)--

The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0-

Published Date: June 18, 1999

Company Name: ThermoGenesis Corp.

Address: 3146 Gold Camp Dr.
 Rancho Cordova, CA 95670

Main Telephone
 Number: 916/858-5100

Internet Home
 Page Address
 (URL) www.thermogenesis.com

Chief Executive
 Officer: Philip H. Coelho

Chief Financial
 Officer: Renee Ruecker, VP

Investor Relations
 Contact: David C. Adams, VP
 Business number: 916/858-5100
 E-mail address: dadams@thermogenesis.com

Public Relations
 Contact: David C. Adams, VP
 Business number: 916/858-5100
 E-mail address: dadams@thermogenesis.com

Industry: Medical device design and manufacture

Trading Symbol/
 Exchange: Nasdaq:KOOL

Market Makers: Paradise Valley Securities; Neidiger,
Tucker, Bruner; Fahnestock & Co.; Spear, Leeds & Kellogg; Neuberger &
Berman


-0-

Company description: ThermoGenesis Corp. ("Company"), founded in 1986, is a leading developer and manufacturer of micro-manufacturing systems designed to harvest Biopharmaceutical drugs from blood.

Biopharmaceutical drugs utilize the body's naturally occurring proteins, enzymes, growth factors, hormones and progenitor cells for the treatment of human disease. ThermoGenesis Corp. Technology Platforms micro-manufacture Biopharmaceutical drugs from a single donation of blood rather than "pools" of blood from thousands of donors or expensive recombinant technology.

The Company believes that micro-manufactured Biopharmaceutical drugs will emerge as the safest, most effective and least expensive treatment for two major medical markets: Wound Care and Cellular Therapy.

The Company's core expertise lies in the areas of thermodynamics and cryopreservation, technologies that it initially applied to ultra rapid freezers and thawers, FDA class I products, sold to blood banks and hospitals in 32 countries throughout the world. Until 4th quarter FY98, the Company's revenues had been principally derived from these core products.

Following four years of intensive research and development, in the 4th quarter of FY98 the Company began shipping its first micro-manufacturing system, the BioArchive(TM) System, a computer controlled liquid nitrogen platform with dedicated disposables for manufacturing and cryopreserving a drug composed of hematopoietic stem and progenitor cells sourced from placental cord blood, which is used to reconstitute the immune system of patients suffering from leukemia, lymphoma, diverse inherited anemias, or hypoproliferative stem cell disorders.

The Company has entered into a period of rapid transformation as it begins the manufacture and marketing of a series of these Biopharmaceutical micro-manufacturing systems with recurring revenues from high margin disposables.

The Company's strategy is to utilize its two new Biopharmaceutical Technology Platforms -- the BioArchive Platform and the CryoSeal(TM) Platform -- as the basis for developing medical devices to micro-manufacture drugs from either autologous or single donor blood which will compete in two major medical markets: Wound Care and Cellular Therapy. -0-

Shares Outstanding: (roughly) 19,764,000
Float: $31 M
EPS: $(.48)
Long Term Debt: $0.00

Fiscal 1999 High Low
First Quarter $2.31 $1.25
Second Quarter $2.69 $0.75
Third Quarter $3.31 $1.75

COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jun 18, 1999
Words:493
Previous Article:Cameron Announces Senior Management Appointments.
Next Article:Corporate Profile for The Horn Group, dated June 18, 1999.


Related Articles
Gene may open new avenue for fighting fat.
ThermoGenesis Announces Product Launch of BioArchive System.
ThermoGenesis Corp. Reports Third Quarter Results; Focus On Enhanced Profit Margins Results in 35% Improvement for Nine Month Reporting Period.
THERMOGENESIS Corp. Licenses BioArchive System Technology to Daido Hoxan, Inc.
ThermoGenesis Corp. Announces New $900,000 Service Contract.
THERMOGENESIS Corp. Announces Results for Fiscal Year 1999.
THERMOGENESIS CORP. Places 2nd BioArchive System in Benelux Region.
THERMOGENESIS CORP. Announces 32% Increase in Revenues for the Quarter Ended December 31, 2000; 'Company Posts A 14% Improvement in Gross Profit...
A toxic side of weight loss: pollutants may slow body's metabolism.
NEAT idea could change office workplace.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters